All In Biotech

Drug Trial Radar · NCT02386839

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care

Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Mar 26, 2015

Primary completion

Sep 28, 2021

Study completion Sep 28, 2021

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Mar 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 weeks, up to 108 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).

Conditions

  • Retinopathy of Prematurity (ROP)

Interventions

  • rhIGF-1/rhIGFBP-3Drug

    Participants who received "rhIGF-1/rhIGFBP-3" in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA)Time frame: At 6 Months CA
  2. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CATime frame: At 12 Months CA
  3. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CATime frame: At 20 Months CA
  4. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CATime frame: At 24 Months CA
  5. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CATime frame: At 4.75 Years CA
  6. Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CATime frame: At 5 Years CA
  7. Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CATime frame: At 12 Months CA
  8. Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CATime frame: At 24 Months CA
  9. Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CATime frame: At 5 Years CA
  10. Number of Participants With Nystagmus at 12 Months CATime frame: At 12 Months CA
  11. Number of Participants With Nystagmus at 24 Months CATime frame: At 24 Months CA
  12. Number of Participants With Nystagmus at 5 Years CATime frame: At 5 Years CA
  13. Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CATime frame: At 6 Months CA
  14. Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CATime frame: At 12 Months CA
  15. Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CATime frame: At 20 Months CA
  16. Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CATime frame: At 4.75 Years CA
  17. Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CATime frame: At 5 Years CA
  18. Number of Participants With Adverse Events (AEs)Time frame: From start of study up to end of study (up to 6.5 years)

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • University of South Alabama Children's and Women's Hospital

    Mobile, Alabama

  • Vidant Medical Center

    Greenville, North Carolina

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e

    Genova, Italy

  • University of Padua

    Padua, Italy

  • Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • VU Medical Center

    Amsterdam, Netherlands

  • Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznan

    Poznan, Poland

  • Skanes Universitetssjukhus Lund

    Lund, Sweden

  • Karolinska Universitetssjukhuset Huddinge

    Stockholm, Sweden

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • St Peter's Hospital

    Chertsey, United Kingdom

  • Alder Hey Childrens Hospital

    Liverpool, United Kingdom

  • UCL EGA Institute for Women's Health

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.